Abiopharma

New Form 8-K - INSMED Inc Filed: 2025-08-07 AccNo: 0001140361-25-029343 Size: 5 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Avalo Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001628280-25-038570 Size: 446 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

XORTX Provides Corporate Update and PlannedActivities for 2025 / 2026

Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Tilray Brands Launches The Humble Seed Whole Wheat Protein Crackers at Whole Foods Market

New Form 10-Q - INSMED Inc Filed: 2025-08-07 AccNo: 0001104506-25-000043 Size: 8 MB

New Form 10-Q - Immunocore Holdings plc Filed: 2025-08-07 AccNo: 0001671927-25-000014 Size: 5 MB

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates